Results
GSK Pharma Q1 FY27 PAT Rises 24% to ₹253 Crore
GSK Pharma reported Q1 FY27 standalone sales of ₹924 crore, up 15% YoY, with PAT growth of 24% to ₹253 crore.
Innovation portfolio including oncology drugs and Shingrix vaccine contributed 7% to sales
